Citations

Clear

13 citation(s) found for "Su, Yixin".

Mechanistic Validation and Structural Analysis of PAH-Associated SOX17 for Real-World Relevance
Chen, Lingtao, Deng, Yuling, Tao, Cui, Nasif, Kazi Fahim Ahmad , Deng, Bobin, Xie, Yixin, Chen, Lingtao , Dai, Zhiyu , Niu, Shuteng , Tao, Cui , Deng, Bobin , Xie, Yixin

Mayo Clinic

2026 IEEE 14th International Conference on Healthcare Informatics (ICHI) | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 574-581

10.1109/ichi69079.2026.00077 Get It

Automatic Molecular Dynamics Simulation with Binding Affinity Prediction Using Deep Learning
Chen, Lingtao , Nasif, Kazi Fahim Ahmad , Deng, Bobin, Yang, Ming , Niu, Shuteng , Xie, Yixin

Mayo Clinic

2025 IEEE 37th International Conference on Tools with Artificial Intelligence (ICTAI) | December 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: 292-298

10.1109/ictai66417.2025.00045 Get It

Marine Microplastic Levels and the Prevalence of Cardiometabolic Diseases in US Coastline Counties
Makwana, Bhargav , Khadke, Sumanth , Kumar, Ashish , Nasir, Khurram , Wadhera, Rishi K. , Shah, Rikin , Sheth, Sudip , Kong, Yixin , Navas‐Acién, Ana , Rajagopalan, Sanjay , Al‐Kindi, Sadeer , Ganatra, Sarju , Wadhera, Rishi K , Al-Kindi, Sadeer , Dani, Sourbha S , Ganatra, Sarju , Kumar, Ashish , Adamkiewicz, Gary , Dani, Sourbha S. , Moffatt‐Bruce, Susan D.

Mayo Clinic

Journal of the American Heart Association | June 18, 2025 | Volume: 14 | Issue: 13 | Pages: No page available

10.1161/jaha.124.039891 | PMID 40528809 Get It

Background Although micro‐ and nanoplastics are an emerging risk factor for the development of cardiovascular diseases, the association of marine microplastic levels (MMLs) with the burden of cardiometabolic diseases at a population level remains unexplored. We investigated the relationship between the mean microplastic concentration in ocean water within 200 nautical miles of the US coastline and the prevalence of type 2 diabetes, coronary artery disease, and stroke in nearby counties. Methods Microplastic concentration data within 200 nautical miles of the US coastline were geospatially analyzed to calculate mean MMLs. The coastal counties were stratified into 4 categories based on MMLs in the adjacent ocean water body: low, medium, high, or very high. The Behavioral Risk Factor Surveillance System 2019 to 2020 survey data were used to identify the prevalence of type 2 diabetes, coronary artery disease, and stroke in these counties. Univariate and population‐weighted multivariate quasi‐Poisson regression, adjusted for county‐level confounding variables, was used to evaluate the unadjusted and adjusted associations between disease prevalence and MMLs. Results The mean age of the population was 43±6 years. After adjusting for age, sex, physician access, and socioenvironmental vulnerabilities at the county level, counties with very high MMLs exhibited an 18%, 7%, and 9% higher adjusted prevalence of type 2 diabetes, coronary artery disease, and stroke, respectively, compared with those with low levels. Conclusion Marine microplastic levels were significantly associated with the prevalence of cardiometabolic diseases in coastal counties. Comprehensive studies at an individual level are needed to further investigate the health impacts of microplastic pollution.
Career transitions and practice patterns among international medical graduates in oncology workforce: A US nationwide analysis.
Tang, Yixin , Neupane, Karun , Larijani, Fatemeh Ardeshir, Lee, Alfred Ian , Gandhi, Shipra, Dizman, Nazlı , Perimbeti, Stuthi, Jiang, Changchuan , Xing, Jiazhang , Wang, Qian , Lu, Chuan Angel , Chen, Fangyuan , Roy, Arya Mariam , Deng, Lei , Bekaii‐Saab, Tanios , Aggarwal, Charu , Owonikoko, Taofeek Kunle , Chávez‐MacGregor, Mariana , Bakouny, Ziad , Gandhi, Shipra , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 9009-9009

10.1200/jco.2025.43.16_suppl.9009 Get It

9009 Background: International Medical Graduates (IMGs) are a vital component of the US oncology workforce, representing nearly half of practicing medical oncologists. However, systemic barriers may influence their career trajectories differently. Understanding these challenges is essential for addressing workforce disparities and optimizing cancer care delivery across diverse geographic regions. Methods: We conducted a cross-sectional study of 13,497 medical oncologists using the 2024 Dec CMS Provider Dataset linked with the 2023 Rural-Urban Continuum Codes (RUCC). Medical oncologists were identified by their self-reported primary specialties, including Hematology/Oncology, Medical Oncology, and Hematopoietic Cell Transplant. Physicians were categorized by graduation origin (based on their self-reported medical school), career stage (early: 0–10 years, mid: 11–30 years, late: >30 years post-medical school graduation). The primary outcomes included practice at Main Campus of NCI Designated Cancer Centers (as an indicator of academic practice) and the geographical location of their practice (Metro, Non-Metro, Mixed). We employed chi-squared tests for statistical comparisons and performed stratified analyses by career stage to evaluate transition patterns over time. Results: 6920 IMGs constituted 48.7% of the oncology workforce, with similar gender distributions between IMG and non-IMG oncologists (37.9% vs 36.5% female, p=0.068). Notably, early career oncologists were less likely to be IMGs (IMG vs non-IMGs: 8.2% vs 12.5%, p<0.001). Compared to Non-IMGs, IMG oncologists are less likely to practice at main campuses of NCI Center (19.9% vs. 27.7%, p<0.001), especially as their career advances (all p<0.01). (Table). IMGs had higher representation in non-metropolitan areas than non-IMGs (11.4% vs 9.1%, p<0.001), particularly in late-career stages (14.7% vs 12.3%, p=0.033), indicating their unique role in serving underserved regions. (Table). Conclusions: Our findings reveal that, IMGs are less likely to practice at main campuses of NCI-Cancer Center than their non-IMG colleagues. Meanwhile, IMG oncologists are disproportionately serving rural communities. Supporting IMG pathways in oncology is critical to ensure a balanced cancer care delivery across the United States. Practice setting distribution and academic affiliation among international medical graduates (IMGs) and US graduates (USGs) by career stage. IMG (N=6,577) Non-IMG (N=6,920) IMG (N=6,577) Non-IMG (N=6,920) NCI Center Other NCI Center Other Metro Non-Metro/Mixed Metro Non-Metro/Mixed Total 19.9% 80.1% 27.7% 72.3% 88.6% 11.4% 90.9% 9.1% Career Stage Early (0-10y) 29.1% 70.9% 36.1% 63.9% 91.1% 8.9% 95.4% 4.6% Mid (11-30y) 21.3% 78.7% 28.8% 71.2% 90.1% 9.9% 91.6% 8.4% Senior (30+y) 15.0% 85.0% 22.0% 78.0% 85.3% 14.7% 87.7% 12.3%
Impact of Marine Microplastics on Neurologic and Functional Disabilities: A Population‐Level Study
Makwana, Bhargav , Desai, Brinda, Srinivasan, Jayashri, Apetauerova, Diana, Sehgal, Siddharth, Yerstein, Oleg , Nasir, Khurram , Kong, Yixin , Rajagopalan, Sanjay , Al‐Kindi, Sadeer , Ganatra, Sarju , Ganatra, Sarju , Desai, Brinda, Dani, Sourbha S. , Khadke, Sumanth , Kumar, Ashish , Wadhera, Rishi K. , Navas‐Acién, Ana , Adamkiewicz, Gary , Moffatt‐Bruce, Susan D.

Mayo Clinic

European Journal of Neurology | May 21, 2025 | Volume: 32 | Issue: 5 | Pages: No page available

10.1111/ene.70144 | PMID 40396917 Get It

ABSTRACTBackgroundMicroplastics are emerging as environmental pollutants with potential neurotoxic effects, yet their association with neurological disabilities remains largely unexplored.MethodsIn this cross‐sectional study comprising 218 coastal counties in the United States, we compared the self‐reported prevalence of cognitive disability, mobility disability, self‐care disability, and independent living disability in counties with very high and low marine microplastic levels (MMLs). Unadjusted and adjusted prevalence ratios (PRs) were computed using population‐weighted quasi‐Poisson regression across three different models to examine the relationship between disability prevalence and MMLs.ResultsCounties exposed to very high marine microplastic levels had a higher mean prevalence of self‐reported cognitive disability (15.2% vs. 13.9%), mobility disability (14.1% vs. 12.3%), self‐care disability (4.2% vs. 3.6%), and independent living disability (8.5% vs. 7.7%) compared to those exposed to low levels (p < 0.001). Regression analyses revealed significantly elevated adjusted prevalence ratios (PRs) for cognitive (PR: 1.09 [95% CI: 1.06–1.12], p < 0.001), mobility (PR: 1.06 [1.03–1.10], p < 0.001), self‐care (PR: 1.16 [1.11–1.20], p < 0.001), and independent living disability (PR: 1.08 [1.05–1.12], p < 0.001) in counties with very high microplastic exposure compared to those with low exposure.ConclusionsThis study highlights a significant association between marine microplastic pollution and the self‐reported prevalence of cognitive, mobility, self‐care, and independent living disabilities at the county level. While merely associative, these findings emphasize the urgent need for further investigation into the individual‐level health impacts of microplastic exposure and underscore the importance of environmental interventions to mitigate potential risks.
APOE- ε4-induced Fibronectin at the blood-brain barrier is a conserved pathological mediator of disrupted astrocyte-endothelia interaction in Alzheimer’s disease
Bhattarai, Prabesh , Yılmaz, Elanur , Cakir, Elif Öykü, Lee, Annie , Ma, Yiyi, Çelikkaya, Hilal , Wang, Xue , Nelson, Nastasia, Nuriel, Tal , Jülich, Dörthe, İş, Özkan , Holley, Scott A., Jager, Philip L. De , Fisher, Elizabeth , Tubbesing, Kate, Temple, Sally , Ertekin‐Taner, Nilüfer , Mayeux, Richard , Teich, Andrew F , Mayeux, Richard , Kizil, Caghan , Cakir, Elif Öykü, Yüceer, Hande , Coşacak, Mehmet İlyas , Haage, Verena Claudia , Lin, Weilin , Zhang, Yixin , Jülich, Dörthe, Holley, Scott A., Tubbesing, Kate, Teich, Andrew F. , Bertucci, Taylor , Vardarajan, Badri Narayan

Mayo Clinic

No container title available | January 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.01.24.634732 | PMID 39975303 Get It

Abstract Blood-brain barrier (BBB) dysfunction is a key feature of Alzheimer’s disease (AD), particularly in individuals carrying the APOE-ε4 allele. This dysfunction worsens neuroinflammation and hinders the removal of toxic proteins, such as amyloid-beta (Aβ42), from the brain. In post-mortem brain tissues and in animal models, we previously reported that fibronectin accumulates at the BBB predominantly in APOE-ε4 carriers. Furthermore, we found a loss-of-function variant in the fibronectin 1 ( FN1 ) gene significantly reduces aggregated fibronectin levels and decreases AD risk among APOE-ε4 carriers. Yet, the molecular mechanisms downstream of fibronectin at the BBB remain unclear. The extracellular matrix (ECM) plays a crucial role in maintaining BBB homeostasis and orchestrating the interactions between BBB cell types, including endothelia and astrocytes. Understanding the mechanisms affecting the ECM and BBB cell types will be critical for developing effective therapies against AD, especially among APOE-ε4 carriers. Here, we demonstrate that APOE-ε4 , Aβ42, and inflammation drive the induction of FN1 expression in several models including zebrafish, mice, iPSC-derived human 3D astrocyte and 3D cerebrovascular cell cultures, and in human brains. Fibronectin accumulation disrupts astroglial-endothelial interactions and the signalling cascade between vascular endothelial growth factor (VEGF), heparin-binding epidermal growth factor (HBEGF) and Insulin-like growth factor 1 (IGF1). This accumulation of fibronectin in APOE-ε4- associated AD potentiates BBB dysfunction, which strongly implicates reducing fibronectin deposition as a potential therapeutic target for AD. Graphical abstract Accessibility text This image illustrates the effects of different APOE isoforms (ApoE-ε3 and ApoE-ε4) on blood-brain barrier (BBB) integrity, focusing on the molecular interactions between astrocytes and endothelial cells. This figure emphasizes the detrimental effects of ApoE-ε4 on BBB integrity via fibronectin accumulation and altered signaling pathways. The top section provides a schematic overview of the blood-brain barrier, highlighting astrocytes, endothelial cells, and their interface. The left panel represents the ApoE-ε3 condition: Normal fibronectin (FN1) levels support healthy interactions between astrocytes and endothelial cells. Growth factors, including VEGFA, HBEGF, and IGF1, maintain BBB integrity through their respective receptors (VEGFR and EGFR). Green arrows indicate activation of these signaling pathways. The right panel depicts the ApoE-ε4 condition: Elevated fibronectin (FN1) disrupts astrocyte-endothelium interactions. FN1 binds integrins and activates focal adhesion kinase (FAK), inhibiting VEGFA, which is required for endothelial HBEGF that in turn activates IGF1 signaling. Red symbols indicate inhibition of HBEGF, VEGFA, and IGF1 pathways, leading to BBB dysfunction. Highlights APOE-ε4 drives fibronectin deposition in Alzheimer’s, disrupting astrocyte-endothelia interactions. APOE-ε4 and fibronectin co-localize, forming aggregates at blood-brain barrier (BBB). Fibronectin alters the signaling between VEGF, IGF1, and HBEGF impairing BBB function. Reducing fibronectin restores BBB integrity and offsets APOE-ε4 pathology.
USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization
Liu, Jiaqi , Zhu, Qian , Zhang, Yixin , Chen, Yuping , Wang, Kaikai , Lou, Zhenkun , Yuan, Jian

Mayo Clinic

CNS Neuroscience & Therapeutics | April 22, 2024 | Volume: 30 | Issue: 4 | Pages: No page available

10.1111/cns.14711 | PMID 38644551 Get It

AbstractObjectiveTo elucidate the relationship between USP19 and O(6)‐methylguanine‐DNA methyltransferase (MGMT) after temozolomide treatment in glioblastoma (GBM) patients with chemotherapy resistance.MethodsScreening the deubiquitinase pannel and identifying the deubiquitinase directly interacts with and deubiquitination MGMT. Deubiquitination assay to confirm USP19 deubiquitinates MGMT. The colony formation and tumor growth study in xenograft assess USP19 affects the GBM sensitive to TMZ was performed by T98G, LN18, U251, and U87 cell lines. Immunohistochemistry staining and survival analysis were performed to explore how USP19 is correlated to MGMT in GBM clinical management.ResultsUSP19 removes the ubiquitination of MGMT to facilitate the DNA methylation damage repair. Depletion of USP19 results in the glioblastoma cell sensitivity to temozolomide, which can be rescued by overexpressing MGMT. USP19 is overexpressed in glioblastoma patient samples, which positively correlates with the level of MGMT protein and poor prognosis in these patients.ConclusionThe regulation of MGMT ubiquitination by USP19 plays a critical role in DNA methylation damage repair and GBM patients’ temozolomide chemotherapy response.
Small extracellular vesicles in plasma reveal molecular effects of modified Mediterranean-ketogenic diet in participants with mild cognitive impairment
Sharma, Mitu, Su, Yixin , Singh, Sangeeta , Hsu, Fang‐Chi , Neth, Bryan J. , Register, Thomas C. , Blennow, Kaj , Zetterberg, Henrik , Craft, Suzanne , Deep, Gagan , Neth, Byran J. , Zetterberg, Henrik , Deep, Gagan , Kumar, Ashish

Mayo Clinic

Brain Communications | October 17, 2022 | Volume: 4 | Issue: 6 | Pages: No page available

10.1093/braincomms/fcac262 | PMID 36337342 Get It

Abstract Extracellular vesicles have emerged as a less-invasive nano-tool for discovering biomarkers of Alzheimer’s disease and related dementia. Here, we analysed different neuron-enriched extracellular vesicles from plasma to predict response and molecular mechanisms of ketogenic diet’s efficacy in mild cognitive impairment participants. The study was a randomized crossover design in which cognitively normal and mild cognitive impairment participants consumed a modified Mediterranean-ketogenic diet or American Heart Association diet for 6 weeks, followed by other diet after washout. L1 cell adhesion molecule, synaptophysin and neural cell adhesion molecule surface markers were used to enrich for neuron-secreted small extracellular vesicles (sEVL1CAM, sEVSYP and sEVNCAM). For the first time, we have presented multiple evidences, including immunogold labelling/transmission electron microscopy, clusters of differentiation 63-ELISA-based assay, confocal microscopy fluorescent images and flow cytometry data confirming the presence of L1 cell adhesion molecule on the surface of sEVL1CAM, validating purity and relative abundance of sEVL1CAM in the plasma. Cargo analysis of sEVL1CAM showed that modified Mediterranean-ketogenic diet intervention reduces amyloid beta 1–42 (50.3%, P = 0.011), p181-tau (34.9%, P = 0.033) and neurofilament light (54.2%, P = 0.020) in mild cognitive impairment participants. Moreover, sEVL1CAMshowed better sensitivity compared with CSF in analysing increased glutamate (6-folds, P &lt; 0.0001) from mild cognitive impairment participants following modified Mediterranean-ketogenic diet intervention. sEVL1CAM characterization also suggested that modified Mediterranean-ketogenic diet differentially targets the expression of various glutamate receptors—glutamate receptor ionotropic NMDA1, glutamate receptor ionotropic NMDA2A, glutamate receptor ionotropic NMDA2B and glutamate receptor ionotropic AMPA type subunit 1. Importantly, these sEVL1CAM measures strongly correlated with corresponding clinical CSF biomarkers (neurogranin, amyloid beta 1–42, neurofilament light and tau). Furthermore, sEVL1CAM were loaded with less advanced glycation endproducts and exhibited anti-inflammatory activity following modified Mediterranean-ketogenic diet intervention. Most importantly, the expression of monocarboxylate transporter 2 on the surface of sEVL1CAM predicted the amyloid beta 1–42 response to modified Mediterranean-ketogenic diet intervention (area under the curve = 0.87, P = 0.0044) and offered a novel screening tool to identify participants responsive to this dietary intervention. Finally, sEVL1CAM, sEVSYP and sEVNCAM showed significantly high concordance in analysing amyloid beta 1–42 (Pearson correlation coefficient ≥ 0.63, P &lt; 0.01) and neurofilament light (Pearson correlation coefficient ≥ 0.49, P &lt; 0.05). Together, small extracellular vesicles in plasma offers promise in assessing the efficacy of dietary/therapeutic intervention against mild cognitive impairment/Alzheimer’s disease.
Influence of the area of the aqueduct and region of interest on quantification of stroke volume in healthy volunteers using phase-contrast cine magnetic resonance imaging
Zhang, Hongri , Yang, Haixin, Duan, Weike , Elder, Benjamin D. , Duan, Weike, Li, Xiaopan , Wang, Yixin, Cogswell, Petrice M.

Mayo Clinic

Acta Radiologica | September 15, 2022 | Volume: 64 | Issue: 4 | Pages: 1615-1622

10.1177/02841851221125916 | PMID 37023028 Get It

Background Phase-contrast cine magnetic resonance imaging (PC-MRI) has been used to measure cerebrospinal fluid (CSF) flow dynamics, but the influence of the area of the aqueduct and region of interest (ROI) on quantification of stroke volume (SV) has not been assessed. Purpose To assess the influence of the area of the ROI in quantifying the aqueductal SV measured with PC-MRI within the cerebral aqueduct. Material and Methods Nine healthy volunteers (mean age = 29.6 years) were enrolled in the study, and brain MRI examinations were performed on a 3.0-T system. Quantitative analysis of the aqueductal CSF flow was performed using manual ROI placement. ROIs were separately drawn for each of the 12 phases of the cardiac cycle, and changes in aqueduct size during the cardiac cycle were determined. The SV was calculated using 12 different aqueductal ROIs and compared with the SV calculated using a fixed ROI size. Results There was variation in the size of the aqueduct during the cardiac cycle. In addition, the measured SV increased with a greater area of the ROI. A significant difference in the calculated SVs with the 12 variable ROIs was observed compared with that using a fixed ROI throughout the cardiac cycle. Conclusion To establish reliable reference values for the SV in future studies, a variable ROI should be considered.
Influence of the Area of the Aqueduct on Quantification of Stroke Volume and Max Velocity in Healthy Volunteers Using Phase Contrast Cine MRI
Zhang, Hongri , Duan, Weike , Wang, Yixin , Elder, Benjamin D. , Duan, Weike, Li, Xiaopan , Li, Xinyu , Cogswell, Petrice M.

Mayo Clinic

No container title available | March 24, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-334057/v1 Get It

Abstract Background: The relationship of the area of the aqueduct on quantification of the aqueductal stroke volume (SV) and max velocity need further investigation. Our aim was to assess the influence of the area of the aqueduct on quantification of the aqueductal SV and max velocity measured with phase contrast magnetic resonance imaging (PC-MRI) within the cerebral aqueduct at the level of the intercollicular sulcus.Materials and Methods: Nine healthy volunteers (mean age 29.6 yrs) were enrolled in the study and brain MRIs were performed on a 3.0T system. Quantitative analysis of aqueductal cerebrospinal fluid (CSF) flow was performed using manual regions of interest (ROI) placement. ROIs were separately drawn for each of 12 phases of the cardiac cycle, and changes in aqueduct size during the cardiac cycle were determined. Stroke volumes were calculated uses the first and ninth aqueductal ROIs and compared to each other. Max velocities at the 12 phases were also collected, and the relationship between the area and max velocity and the impact on SV were analyzed.Results: There was variation in the size of the aqueduct during the cardiac cycle, the first area(S1)was larger than the ninth(S9). The first max velocity(Vmax1)was less than the ninth(Vmax9). Additionally, there was a significant different between the stroke volume calculated using the first aqueductal ROI (SV1) and the ninth(SV9). Conclusions: There is variation in the size of the cerebral aqueduct which is used to calculate stroke volume and other CSF flow parameters during the cardiac cycle. The maximum velocity may be inversely proportional to the area of ​​the aqueduct. In order to establish reliable reference values for CSF flow parameters in future studies, a variable ROI, to account for cardiac cycle variation, should be considered and incorporated.